• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk of hepatitis B virus reactivation in patients treated with ibrutinib.

作者信息

Hammond Sarah P, Chen Kaiwen, Pandit Alisha, Davids Matthew S, Issa Nicolas C, Marty Francisco M

机构信息

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA; and.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

出版信息

Blood. 2018 Apr 26;131(17):1987-1989. doi: 10.1182/blood-2018-01-826495. Epub 2018 Feb 28.

DOI:10.1182/blood-2018-01-826495
PMID:29490923
Abstract
摘要

相似文献

1
Risk of hepatitis B virus reactivation in patients treated with ibrutinib.接受依鲁替尼治疗的患者中乙型肝炎病毒再激活的风险。
Blood. 2018 Apr 26;131(17):1987-1989. doi: 10.1182/blood-2018-01-826495. Epub 2018 Feb 28.
2
Severe hepatitis B virus reactivation related to ibrutinib monotherapy.与伊布替尼单药治疗相关的严重乙型肝炎病毒再激活
Ann Hematol. 2017 Apr;96(4):689-690. doi: 10.1007/s00277-016-2917-2. Epub 2017 Jan 5.
3
Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment.芦可替尼治疗期间隐匿性乙型肝炎病毒感染患者的病毒再激活风险。
Ann Hematol. 2019 Jan;98(1):215-218. doi: 10.1007/s00277-018-3405-7. Epub 2018 Jun 26.
4
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.在未进行病毒预防的情况下接受依鲁替尼治疗的隐匿性HBV感染的CLL患者中HBV再激活。
Leuk Lymphoma. 2019 May;60(5):1340-1342. doi: 10.1080/10428194.2018.1523401. Epub 2019 Feb 7.
5
Occult HBV reactivation induced by ibrutinib treatment: a case report.依鲁替尼治疗引起的隐匿性乙肝病毒再激活：一例报告
Acta Gastroenterol Belg. 2015 Dec;78(4):424-6.
6
Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.慢性淋巴细胞白血病患者乙肝病毒（HBV）再激活抗病毒控制后使用依鲁替尼治疗的可行性和安全性。
Leuk Lymphoma. 2018 Nov;59(11):2734-2736. doi: 10.1080/10428194.2018.1436175. Epub 2018 Feb 21.
7
Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.十八个月拉米夫定预防在接受免疫抑制治疗的血液系统恶性肿瘤患者中预防隐匿性乙型肝炎病毒感染再激活的作用
J Viral Hepat. 2018 Feb;25(2):198-204. doi: 10.1111/jvh.12802. Epub 2017 Nov 29.
8
Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.拉米夫定预防化疗治疗的血液系统恶性肿瘤乙肝病毒携带者乙肝再激活——一项前瞻性病例系列研究
Am J Hematol. 2005 Nov;80(3):197-203. doi: 10.1002/ajh.20471.
9
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.血液系统恶性肿瘤患者在完成细胞毒性化疗后停用抢先使用的拉米夫定后发生的乙型肝炎再激活。
Gut. 2005 Nov;54(11):1597-603. doi: 10.1136/gut.2005.070763. Epub 2005 Jul 6.
10
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.依鲁替尼治疗患者大出血的发生率和风险因素：一项综合分析。
Br J Haematol. 2019 Feb;184(4):558-569. doi: 10.1111/bjh.15690. Epub 2018 Dec 2.

引用本文的文献

1
Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors.接受布鲁顿酪氨酸激酶抑制剂治疗的血液系统恶性肿瘤患者中的乙型肝炎病毒再激活
Blood Res. 2025 Aug 15;60(1):45. doi: 10.1007/s44313-025-00093-3.
2
Drug-Induced Liver Injury Associated With Emerging Cancer Therapies.与新兴癌症治疗相关的药物性肝损伤
Liver Int. 2025 Feb;45(2):e70002. doi: 10.1111/liv.70002.
3
Management of infections for patient treated with ibrutinib in clinical practice.临床实践中接受依鲁替尼治疗患者的感染管理
Front Oncol. 2024 Sep 10;14:1428464. doi: 10.3389/fonc.2024.1428464. eCollection 2024.
4
Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments.血液恶性肿瘤治疗中乙型肝炎病毒再激活导致肝失代偿的风险。
World J Gastroenterol. 2024 Jul 7;30(25):3147-3151. doi: 10.3748/wjg.v30.i25.3147.
5
Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024).布鲁顿酪氨酸激酶抑制剂安全性临床管理的循证专家共识（2024年）
Chin J Cancer Res. 2024 Jun 30;36(3):240-256. doi: 10.21147/j.issn.1000-9604.2024.03.02.
6
Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors.在布鲁顿酪氨酸激酶抑制剂时代探索乙型肝炎病毒再激活的复杂领域。
World J Gastroenterol. 2024 Jun 7;30(21):2748-2750. doi: 10.3748/wjg.v30.i21.2748.
7
Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents.慢性淋巴细胞白血病：靶向药物时代不良事件的管理
Cancers (Basel). 2024 May 24;16(11):1996. doi: 10.3390/cancers16111996.
8
Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis.肿瘤患者接受酪氨酸激酶抑制剂治疗后乙型肝炎病毒再激活的风险：病例报告及文献分析。
World J Gastroenterol. 2024 Mar 7;30(9):1253-1256. doi: 10.3748/wjg.v30.i9.1253.
9
Risk of Hepatitis B Reactivation in Patients Receiving Ibrutinib: The National Veterans Affairs Cohort.接受伊布替尼治疗的患者发生乙型肝炎病毒再激活的风险：美国退伍军人事务部队列研究
Open Forum Infect Dis. 2024 Jan 10;11(3):ofae008. doi: 10.1093/ofid/ofae008. eCollection 2024 Mar.
10
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.靶向治疗时代血液系统恶性肿瘤患者乙型肝炎病毒再激活的预防与管理。
World J Gastroenterol. 2023 Sep 7;29(33):4942-4961. doi: 10.3748/wjg.v29.i33.4942.